This was of great significance for the early screening of CML patients, the accompanying diagnosis during the treatment process, the discovery of new BCR::ABL1 mutation subtypes, and subsequent intervention and treatment. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.